I-Mab Announces Encouraging Phase 1b/2 Study Results of Pati

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells....

Related Keywords

Gaithersburg , Maryland , United States , China , Lishui , Zhejiang , Hong Kong , Qing Zhou , Guangdong , Shanghai , Jilin , Hangzhou , Long Wu , Hubei , San Diego , California , Beijing , American , Andrew Zhu , Richard Yeh , Gigi Feng , Guangdong Academy Of Medical Sciences , Exchange Commission , Prnewswire The Company Nasdaq , Guangdong Lung Cancer Institute , American Society Of Clinical Oncology , Linkedin , Nasdaq , Twitter , Clinical Oncology , Principal Investigator , Guangdong Provincial People , Guangdong Academy , Medical Sciences , Guangdong Lung Cancer , Toripalimab Combination Therapy , Trial Results Using , Potential Predictive Biomarker , Private Securities Litigation Reform Act , Operating Officer , Chief Financial , I Mab , Pharmaceuticals , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,